At the end of 2012, the annual value of the global pharmaceutical market was about EUR 900 billion. Oriola-KD operates on pharmaceutical markets with an annual value of about EUR 18.5 billion* **. The biggest of these markets is Russia, which has an annual value of about EUR 12 billion. The Swedish market is valued at about EUR 3.5 billion and the Finnish market at about EUR 2 billion. The Estonian, Latvian and Lithuanian markets combined are valued at about EUR 1 billion.
In all its markets, Oriola-KD’s pharmaceutical wholesale business operates under the Oriola brand. Oriola-KD is the second largest operator on the Finnish and Swedish markets. Oriola-KD's market share of the Finnish pharmaceutical wholesale market was about 45 per cent, while in Sweden Oriola-KD's share of the wholesale trade was about 38 per cent during the first quarter in 2014. With a market share of about six per cent, Oriola-KD is the sixth largest pharmaceutical wholesaler in Russia.
Oriola-KD engages in retail operations in Russia and Sweden. In Sweden, Oriola-KD operates under the Kronans Apotek brand and in Russia under the Stary Lekar and 03 Apteka brands. Oriola-KD is the third largest operator in Sweden with a market share of about 21 per cent and the seventh largest operator on the Russian pharmaceutical retail market with a market share of about three per cent in the Moscow region.
* wholesale prices in Finland, Sweden, the Baltic countries and Russia
** IMS Health Market Prognosis 2013-2017
Russia is Oriola-KD’s largest and fastest-growing market.